Business
VALEO PHARMA RAISES Q4 AND FULL YEAR 2022 REVENUE GUIDANCE
VALEO PHARMA RAISES Q4 AND FULL YEAR 2022 REVENUE GUIDANCE.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nVALEO PHARMA RAISES Q4 AND FULL YEAR 2022 REVENUE GUIDANCE\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nVALEO PHARMA RAISES Q4 AND FULL YEAR 2022 REVENUE GUIDANCE\nCanada NewsWire\nMONTREAL, Nov. 15, 2022\n\n\n\nQ4-2022 revenue guidance raised to a record $12.5M - $13.0MFiscal 2022 revenue guidance increased to a record $27.5M - $28.0MMONTREAL, Nov. 15, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\") a Canadian pharmaceutical company, today announced that it has raised revenue guidance for its fourth quarter of 2022 to $12.5 - $13.0 million, an increase of 14% to 18% over previously issued guidance of $11 million. The Company is also increasing its fiscal 2022 revenue guidance to $27.5 – 28.0 million, a forecasted increase exceeding 100% compared to fiscal 2021 revenues of $13.6 million.\n\n \n \n \n \n \n \n\n \nThe quarterly and yearly revenue increases result from the continued growth of the two innovative asthma therapies Enerzair® Breezhaler® and Atectura® Breezhaler® and the low molecular weight heparin biosimilar REDESCA™, as well as the  additional revenues generated in the fourth quarter by the recently added ophthalmology products XIIDRA®, SIMBRINZA®, and the epinephrine auto-injector ALLERJECT®.\n\"Our lead products have delivered the strong growth we forecasted for 2022. With a first full year of commercial activities for Enerzair and Atectura now completed,  both products are generating strong sequential quarterly  increases in the number of total prescribers, total prescriptions and revenues\", said Steve Saviuk, CEO. \"The recent addition of our ophthalmic and severe allergy products in early August materially impacted our fourth quarter  and we expect them to significantly contribute to our overall 2023 revenues as well\".   \nAbout Valeo Pharma Inc.Valeo Pharma is a fast growing pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respirology/Al...